Journal of Diabetes and Its Complications
Volume 18, Issue 1 , Pages 60-68 , 2 January 2004

Hypoglycemia as a barrier to glycemic control

  • Stephen Davis

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1-615-936-1653; fax: +1-615-936-1667
    • Division of Diabetes and Endocrinology, Vanderbilt University Hospital, Room 712, MRBII, Nashville, TN 37232, USA
    • ,
  • Miriam D. Alonso

      Affiliations

    • Ingenix Medical Education, Basking Ridge, NJ, USA

Received 5 February 2003 ,Revised 23 April 2003 ,Accepted 1 May 2003.

References 

  1. Abraira C, Colwell J, Nuttall F, Sawin CT, Henderson W, Comstock JP, et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Archives of Internal Medicine. 1997;157:181–188
  2. American College of Endocrinology/American Association of Clinical Endocrinologists (ACE/AACE). ACE consensus statement on guidelines for glycemic control. Endocrine Practice. 2002;8(Suppl. 1):5–40
  3. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2003;26(Suppl. 1):S33–S50
  4. American Diabetes Association. Physical activity/exercise and diabetes mellitus. Diabetes Care. 2003;26(Suppl. 1):S73–S77
  5. American Diabetes Association. Insulin administration. Diabetes Care. 2003;26(Suppl. 1):S121–S124
  6. American Diabetes Association. Diabetic nephropathy. Diabetes Care. 2003;26(Suppl. 1):S94–S98
  7. Anderson JH, Brunelle RL, Koivisto VA, Pfutzner A, Trautmann ME, Vignati L, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes. 1997;46:265–270
  8. Austin EJ, Deary IJ. Effects of repeated hypoglycemia on cognitive function: a psychometrically validated reanalysis of the Diabetes Control and Complications Trial data. Diabetes Care. 1999;22:1273–1277
  9. Bell DSH, Yumuk V. Frequency of severe hypoglycemia in patients with non-insulin-dependent diabetes treated with sulfonylurea or insulin. Endocrine Practice. 1997;3:281–283
  10. Ben-Ami H, Nagachandran P, Mendelson A, Edoute Y. Drug-induced hypoglycemic coma in 102 diabetic patients. Archives of Internal Medicine. 1999;159:281–284
  11. Bischof MG, Ludwig C, Hofer A, Kletter K, Krebs M, Stingl H, et al. Hormonal and metabolic counterregulation during and after high-dose insulin-induced hypoglycemia in diabetes mellitus type. Hormone and Metabolic Research. 2000;32:417–423
  12. Brange J, Owens DR, Kang S, Volund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care. 1990;13:923–954
  13. Brange J, Volund A. Insulin analogs with improved pharmacokinetic profiles. Advanced Drug Delivery Reviews. 1999;35:307–335
  14. Brouhard BH. Long-term neurological consequences of hypoglycemia. Diabetes Care. 1992;15:583–584
  15. Burge MR, Schade DS. Insulins. Endocrinology and Metabolism Clinics of North America. 1997;26:575–598
  16. Burge MR, Schmitz-Fiorentino K, Fischette C, Qualls CR, Schade DS. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus. JAMA. 1998;279:137–143
  17. Campbell RK. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Annals of Pharmacotherapy. 1998;32:1044–1052
  18. Carroll MF, Izard A, Riboni K, Burge MR, Schade DS. Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues. Diabetes Care. 2002;25:2147–2152
  19. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates on diabetes. (2002). Available at: http://www.cdc.gov/diabetes/pubs/estimates.htm. Accessed April 14, 2003.
  20. Chung M, Kourides I, Canovatchel W, Sutfin T, Messig M, Chaiken RL. Pharmacokinetics and pharmacodynamics of extended-release glipizide GITS compared with immediate-release glipizide in patients with type II diabetes mellitus. Journal of Clinical Pharmacology. 2002;42:651–657
  21. Clarke WL, Cox DJ, Gonder-Frederick LA, Julian D, Schlundt D, Polonsky W. Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms. Diabetes Care. 1995;18:517–522
  22. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia. 2002;45:937–948
  23. Davis SN, Galassetti P, Wasserman DH, Tate D. Effects of antecedent hypoglycemia on subsequent counterregulatory responses to exercise. Diabetes. 2000;49:73–81
  24. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Annals of Internal Medicine. 1999;131:281–303
  25. Diabetes Control and Complications Trial (DCCT) Research Group. Weight gain associated with intensive therapy in the Diabetes Control and Complications Trial. Diabetes Care. 1988;11:567–573
  26. Diabetes Control and Complications Trial (DCCT) Research Group. Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. American Journal of Medicine. 1991;90:450–459
  27. Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine. 1993;329:977–986
  28. Diabetes Control and Complications Trial (DCCT) Research Group. Adverse events and their association with treatment regimens in the Diabetes Control and Complications Trial. Diabetes Care. 1995;18:1415–1427
  29. Diabetes Control and Complications Trial (DCCT) Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes. 1997;46:271–286
  30. In:  Edelman SV,  Henry RR editor. Diagnosis and management of type 2 diabetes. 4th ed.. Caddo, OK: Professional Communications; 2001;
  31. Fanelli CG, Pampanelli S, Porcellati F, Bolli GB. Shift of glycaemic thresholds for cognitive function in hypoglycaemia unawareness in humans. Diabetologia. 1998;41:720–723
  32. Frier B. Hypoglycaemia—clinical consequences and morbidity. International Journal of Clinical Practice. 2000;51–55 Suppl
  33. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time–action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 2000;23:644–649
  34. Heise T, Weyer C, Serwas A, Heinrichs S, Osinga J, Roach P, et al. Time–action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care. 1998;21:800–803
  35. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS. Intensive conventional insulin therapy for type II diabetes: metabolic effects during a 6-mo outpatient trial. Diabetes Care. 1993;16:21–31
  36. Hepburn DA, Deary IJ, Frier BM, Patrick AW, Quinn JD, Fisher BM. Symptoms of acute insulin-induced hypoglycemia in humans with and without IDDM. Factor-analysis approach. Diabetes Care. 1991;14:949–957
  37. Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE, et al. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care. 2001;24:983–988
  38. Holleman F, Hoekstra JBL. Insulin lispro. New England Journal of Medicine. 1997;337:176–183
  39. Holstein A, Plaschke A, Egberts E-H. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes/Metabolism Research and Reviews. 2001;17:467–473
  40. Joslin Diabetes Center & Joslin Clinic. (2002). Joslin Diabetes Center & Joslin Clinic clinical guideline for adults with diabetes. Available at: http://diabetesmanagement.joslin.org/Guidelines/Adult_ClinGuide.pdf. 2002.
  41. Kerr D. Continuous blood glucose monitoring: detection and prevention of hypoglycaemia. International Journal of Clinical Practice. 2001;43–46
  42. Koivisto VA, Yki-Järvinen H, Helve E, Karonen S-L, Pelkonen R. Pathogenesis and prevention of the dawn phenomenon in diabetic patients treated with CSII. Diabetes. 1986;35:78–82
  43. Landstedt-Hallin L, Adamson U, Lins P-E. Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism. 1999;84:3140–3145
  44. Leporc M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPII insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142–2148
  45. MacLeod KM. Hypoglycaemia unawareness: causes, consequences and treatment. Journal of the Royal College of Physicians of London. 2000;34:245–250
  46. Metzger M, Leibowitz G, Wainstein J, Glaser B, Raz I. Reproducibility of glucose measurements using the glucose sensor. Diabetes Care. 2002;25:1185–1191
  47. Mitrakou A, Ryan C, Veneman T, Mokan M, Jenssen T, Kiss I, et al. Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol. 1991;260:E67–E74
  48. Ovalle F, Fanelli CG, Paramore DS, Hershey T, Craft S, Cryer PE. Brief twice-weekly episodes of hypoglycemia reduce detection of clinical hypolycemia in type 1 diabetes mellitus. Diabetes. 1998;47:1472–1479
  49. Pitzer KR, Desai S, Dunn T, Edelman S, Jayalakshmi Y, Kennedy J, et al. Detection of hypoglycemia with the Gluco Watch biographer. Diabetes Care. 2001;24:881–885
  50. Porter PA, Bryne G, Stick S, Jones TW. Nocturnal hypoglycaemia and sleep disturbances in young teenagers with insulin dependent diabetes mellitus. Archives of Disease in Childhood. 1996;75:120–123
  51. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA  for the U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care. 2000;23:639–643
  52. Reichard P, Britz A, Rosenqvist U. Intensified conventional insulin treatment and neuropsychological impairment. BMJ. 1991;303:1439–1442
  53. Rosak C, Haupt E, Walter T, Werner J. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia. Diabetes, Nutrition & Metabolism. 2002;15:143–151
  54. Santiago JV, Levandoski LA. Hypoglycemia in patients with type 1 diabetes. In:  Lebovitz HE editors. Therapy for diabetes mellitus and related disorders. 3rd ed.. Alexandria, VA: American Diabetes Association; 1998;p. 241–251
  55. Segel SA, Paramore DS, Cryer PE. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes. 2002;51:724–733
  56. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Archives of Internal Medicine. 1997;157:1681–1686
  57. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412
  58. Torjesen PA, Birkeland KI, Anderssen SA, Hjermann I, Holme I, Urdal P. Lifestyle changes may reverse development of the insulin resistance syndrome. The Oslo Diet and Exercise Study: a randomized trial. Diabetes Care. 1997;20:26–31
  59. Towler DA, Havlin CE, Craft S, Cryer P. Mechanism of awareness of hypoglycemia. Perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms. Diabetes. 1993;42:1791–1798
  60. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  61. Veneman T, Mitrakou A, Mokan M, Cryer P, Gerich J. Induction of hypoglycemia unawareness by asymptomatic nocturnal hypoglycemia. Diabetes. 1993;42:1233–1237
  62. Weyer C, Heise T, Heinemann L. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care. 1997;20:1612–1614
  63. White NH, Skor DA, Cryer PE, Levandoski LA, Bier DM, Santiago JV. Identification of type I diabetic patients at increased risk for hypoglycemia during intensive therapy. New England Journal of Medicine. 1983;308:485–491
  64. Yki-Järvinen H, Dressler A, Ziemen M  for the HOE 901/3002 Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care. 2000;23:1130–1136

☆ Ingenix is owned by UnitedHealth Group.

PII: S1056-8727(03)00058-8

doi: 10.1016/S1056-8727(03)00058-8

Journal of Diabetes and Its Complications
Volume 18, Issue 1 , Pages 60-68 , 2 January 2004

Article Tools

* Image Usage & Resolution